Technology | December 06, 2011

Boston Scientific Receives FDA Clearance for New ICDs, CRT-Ds

December 6, 2011 — Boston Scientific Corp. announced U.S. Food and Drug Administration (FDA) approval of its Incepta, Energen and Punctua cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs). The devices are indicated to treat heart failure and sudden cardiac death. 

They offer enhanced therapy options, advanced battery longevity and a DF4 universal connector system in a small, thin platform. The first implant of the Incepta ICD occurred Nov. 29 at the University of Washington Medical Center in Seattle; the procedure was performed by Jeanne E. Poole, M.D., FHRS, FACC, professor of medicine and director, Arrhythmia Service and Electrophysiology Laboratory.

"These devices are a direct response to what patients tell us they want the most — small, thin, long-lasting devices that provide appropriate therapy when necessary," said Poole. "Additionally, these devices are designed to streamline the implant procedure with Boston Scientific's 4-SITE DF4 connector system."

The connector system reduces the volume of the company’s single-chamber ICDs to 30.5cc and CRT-Ds to 32cc, while maintaining a thickness of less than 10mm. The 4-SITE system is also designed to simplify and reduce the time needed for the implant procedure; it accomplishes this by combining three separate lead terminals into one integrated connection and leveraging the new EZ-4 Connector Tool. This allows physicians to reduce the number of steps required during implant.

Each of the new devices also features options to integrate with the Latitude Heart Failure Management weight scale and blood pressure cuff sensors. In this way they can promote appropriate therapy, reduce right ventricular pacing and improve patient management. 

"Including remote monitoring as a standard for patients will assist physicians involved in the management of this very complex disease.  By involving patients in that process, it could also motivate them to become more engaged in their own care," said Leslie A. Saxon, M.D., chief of cardiovascular medicine at University of Southern California. Saxon is also committee chair of the ALTITUDE clinical program sponsored by Boston Scientific.  "In the ALTITUDE Survival study, patients with remote monitoring had a lower mortality rate."

For more information: www.bostonscientific.com

Related Content

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Overlay Init